IVVD
Invivyd, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.76
+1.22%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.76
From 52W high−73.77%
Volume6.25M
Market cap$222.63M
P/E (TTM)—
P/S (TTM)3.8x
Div yield—
Key dataSep 18, 2026
Open
$0.76
From 52W high
−73.77%
Volume
6.25M
Market cap
$222.63M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
42.5
MomentumView details →
1D Return
+1.22%
YTD Return
−70.14%
SummaryUpdated Jun 1, 2026
Invivyd, Inc. (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company founded in 2020 and based in Waltham, Massachusetts. Originally incorporated as Adagio Therapeutics, the company went public in August 2021 and later rebranded to Invivyd. The company specializes in developing monoclonal antibody therapies specifically designed to protect immunocompromised patients from infectious diseases, with its primary focus on COVID-19 prevention and treatment. Invivyd has successfully brought its lead product <b>PEMGARDA</b> to market and is actively developing next-generation antibody treatments while expanding its pipeline to include other respiratory viruses.
Similar companies
Latest newsMore news →
Invivyd, Inc. appointed Ajay Royan as Lead Independent Director, effective August 30, 2026.19d agoInvivyd, Inc. appointed Marc Elia as Chief Executive Officer and Chairman of the Board, effective August 30, 2026.19d agoInvivyd, Inc. announced its financial results for the second quarter ended June 30, 2026, and recent business highlights.38d ago